Search results
Showing 31 to 45 of 64 results for metastatic prostate cancer
Awaiting development [GID-TA11114] Expected publication date: TBC
High-intensity focused ultrasound for prostate cancer (IPG118)
Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.
Awaiting development [GID-TA11202] Expected publication date: TBC
TA721 Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] 3...
Awaiting development [GID-TA11534] Expected publication date: TBC
Spinal metastases and metastatic spinal cord compression (NG234)
This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.
Awaiting development [GID-TA11049] Expected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
In development [GID-TA10904] Expected publication date: TBC
In development [GID-TA10696] Expected publication date: TBC
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.